首页  | 双语新闻

英国成为首个批准新冠疫苗的西方国家 下周开始接种 UK is 1st country to approve Pfizer COVID-19 vaccine, with distribution to start next week

中国日报网 2020-12-03 15:02




A small shopping basket filled with vials labeled "COVID-19 - Coronavirus Vaccine" is placed on a UK flag in this illustration taken November 29, 2020. Picture taken November 29, 2020. REUTERS/Dado Ruvic


Britain has become the first country in the West to approve a COVID-19 vaccine for public use. The UK Department of Health and Social Care confirmed in a statement to British news agencies that the vaccine developed jointly by American drugmaker Pfizer and Germany's BioNTech would be distributed starting next week. Pfizer was the first of three major Western pharmaceutical companies to apply in both the US and Europe for emergency use authorization.



"The Government has today accepted the recommendation from the independent Medicines and Healthcare products Regulatory Agency (MHRA) to approve Pfizer/BioNTech's Covid-19 vaccine for use," a Department of Health and Social Care spokesman told the Press Association of Britain. The spokesman said the emergency use authorization followed "months of rigorous clinical trials and a thorough analysis of the data by experts at the MHRA who have concluded that the vaccine has met its strict standards of safety, quality and effectiveness."



In line with planning in the US, British front-line healthcare workers, care home residents, the very elderly and people with underlying conditions that make them particularly vulnerable to COVID-19 complications are expected to get the first doses of the vaccine. Pfizer's vaccine, like the Oxford and Moderna formulas, requires two doses about a month apart.



UK Health Secretary Matt Hancock called it "fantastic news" that Britain's regulator had deemed the first vaccine safe, and vowed that distribution would begin from Monday. He told the BBC Breakfast show that vaccinations would "start with the most elderly and with people in care homes."



Prime Minister Boris Johnson also hailed the news, confirming in a tweet plans to start rolling out doses from next week.



Screenshot from CBS website


"It's the protection of vaccines that will ultimately allow us to reclaim our lives and get the economy moving again," Johnson said.



Hancock, Britain's top public health official, noted the logistical complexities of distributing the Pfizer vaccine, which needs to be stored at around -94 degrees Fahrenheit, but said Britain would get its first 800,000 doses delivered next week. The UK has a total of 40 million doses of the Pfizer vaccine on order, enough to fully treat 20 million people.



A dose of the coronavirus disease (COVID-19) vaccination of BioNTech and Pfizer is pictured in this undated handout photo, as Britain became the first western country to approve a COVID-19 vaccine, in Mainz, Germany. BioNTech SE 2020, all rights reserved/Handout via REUTERS


Two other vaccines, one developed by US-based Moderna, which also requires sub-zero storage, and one made by British pharmaceutical company AstraZeneca in conjunction with Oxford University, have also applied for emergency use authorization in the US and Europe.



Both Pfizer and Moderna have said that data from large-scale human trials, involving tens of thousands of people, showed their vaccines to be about 95% effective at preventing COVID-19 infection. AstraZeneca/Oxford found their vaccine, which works in a different way, was up to 90% effective with a certain dosing regimen. The Oxford-developed vaccine is much cheaper to produce, and to distribute as it only requires storage at refrigerator temperatures.



Pfizer chief executive Albert Bourla called the UK move "a historic moment in the fight against COVID-19."



None of the human trials on any of the three leading Western-made vaccines have found significant adverse affects. Some side effects commonly associated with long-used vaccines, including soreness around the point of injection, fatigue and headaches have been seen in the trial data.



A dose of the coronavirus disease (COVID-19) vaccination of BioNTech and Pfizer is pictured in this undated handout photo, as Britain became the first western country to approve a COVID-19 vaccine, in Mainz, Germany. BioNTech SE 2020, all rights reserved/Handout via REUTERS


Logistical issues aside, epidemiologists and public health officials worldwide have warned that another major hurdle to putting the coronavirus pandemic behind humanity could be mistrust of the vaccines that become available.



A CBS News poll carried out in early September found rising skepticism about the coronavirus vaccines in development, with most voters saying that if a vaccine were made available this year, their first thought would be that it was rushed through without enough testing.



Just 21% of voters nationwide said in the survey that they would get a vaccine as soon as possible if it were available at no cost, which was down from 32% in a survey conducted in late July. Most said they would consider it, but wait to see what happens to others before getting one themselves.



This pandemic has seen pharmaceutical companies and research institutes work with governments and independent regulatory agencies to compress the usually-years-long process of developing and approving vaccines into a much shorter time frame.



The pace has been completely unprecedented, but the entities involved, along with outside experts in infectious disease and vaccinology, have insisted throughout that the process is being compressed safely, largely by overlapping steps that normally come sequentially, rather than by eliminating any steps in the trial and certification process.


overlap[ˌoʊvərˈlæp]: v. 在时间上部分地重叠,同时发生


Hancock, the British government's health chief, told UK broadcaster Piers Morgan on Wednesday that, if they could get it approved even though they weren't in a high-risk group, he would happily get vaccinated live on television next week with Morgan to show his trust in the vaccine.





中国日报网 英语点津微信
中国日报网 双语小程序